Subsequent Event	6 Months Ended
Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Event	22. Subsequent event – On July 1, 2019, AMVAC completed the acquisition of certain rights and the assumption of certain liabilities relating to three product lines (etoxazole, bispyribac sodium and diflubenzuron) from Raymat Crop Science, Inc. (and certain of its affiliates). The purchase price was immaterial to the condensed consolidated financial statements. With respect to etoxazole and bispyribac sodium, AMVAC obtained registrations, trademarks (“Stifle” and “Arroz 80”) and inventories. With respect to diflubenzuron, AMVAC became the exclusive distributor of end-use products within the United States.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration